RIVA研究:利妥昔单抗联合瓦立鲁单抗治疗复发或难治性B细胞恶性肿瘤的IIa期随机对照试验方案
RIVA是一项在复发或难治性CD20阳性B细胞淋巴瘤患者中开展的两阶段、开放标签、随机IIa期试验,最多纳入40例患者,1:1随机接受两种不同剂量的瓦立鲁单抗(抗CD27单抗)联合利妥昔单抗(抗CD20单抗)方案。主要目的是评估联合方案的安全性和耐受性及抗肿瘤活性,次要目标包括缓解持续时间和总生存期,并开展B细胞清除、免疫效应细胞变化、CD27表达及药代动力学等转化研究。研究结果将为后续II/III期试验提供依据。
要点
- RIVA试验评估利妥昔单抗联合瓦立鲁单抗在复发或难治性B细胞淋巴瘤中的安全性和抗肿瘤活性。
- 研究采用两阶段开放标签随机设计,最多纳入40例患者,1:1随机接受两种不同联合方案。
- 转化研究将评估B细胞清除、免疫效应细胞变化、CD27作为疗效生物标志物及药代动力学。
核心结论
- RIVA试验将确定利妥昔单抗联合瓦立鲁单抗在复发或难治性B细胞恶性肿瘤中是否具有活性和安全性,为后续II/III期试验提供依据。
研究设计与样本
- RIVA是一项两阶段、开放标签、随机IIa期试验,最多纳入40例低级别或高级别复发或难治性CD20阳性B细胞淋巴瘤患者,在英国招募。
- 入组患者按1:1随机分配至两种不同的瓦立鲁单抗与利妥昔单抗联合方案组。
关键数值与推荐
- 主要目标为确定联合方案的安全性和耐受性及抗肿瘤活性(缓解)。
- 次要目标包括缓解持续时间和总生存期评估。
- 转化目标包括评估B细胞清除、免疫效应细胞群体变化、CD27表达作为缓解生物标志物及药代动力学特性。
- 分析未设定正式统计比较的效能。
局限性
- 分析未设定正式统计比较的效能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Over 12,000 new cases of B-cell malignancies are diagnosed in the UK each year, with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) being the most common subtypes. Standard frontline therapy consists of immunochemotherapy with a CD20 monoclonal antibody (mAb), such as rituximab, delivered in combination with multi-agent chemotherapy. Despite being considered a treatable and potentially curable cancer, approximately 30% of DLBCL cases will relapse after frontline therapy. Advanced stage FL is incurable and typically has a relapsing and remitting course with a frequent need for re-treatment. Based on supportive preclinical data, we hypothesised that the addition of varlilumab (an anti-CD27 mAb) to rituximab (an anti-CD20 mAb) can improve the rate, depth and duration of the response of rituximab monotherapy in patients with relapsed or refractory B-cell malignancies. METHODS/DESIGN: Combination treatment of varlilumab plus rituximab, in two different dosing regimens, is being tested in the RIVA trial. RIVA is a two-stage open-label randomised phase IIa design in up to 40 patients with low- or high-grade relapsed or refractory CD20+ B-cell lymphoma. The study is open to recruitment in the UK. Enrolled patients are randomised 1:1 to two different experimental varlilumab to rituximab combinations. The primary objective is to determine the safety and tolerability of the combination and the anti-tumour activity (response) in relapsed or refractory B-cell malignancies. Secondary objectives will include an evaluation of the duration of the response and overall survival. Tertiary translational objectives include assessment of B-cell depletion, changes in immune effector cell populations, expression of CD27 as a biomarker of response and pharmacokinetic properties. Analyses will not be powered for formal statistical comparisons between treatment arms. DISCUSSION: RIVA will determine whether the combination of rituximab and varlilumab in relapsed or refractory B-cell malignancies is active and safe prior to future phase II/III trials. TRIAL REGISTRATION: EudraCT, 2017-000302-37. Registered on 16 January 2017. ISRCTN, ISRCTN15025004 . Registered on 16 August 2017.
引用
- Lim SH, Linton KM, Collins GP, et al. RIVA - a phase IIa study of rituximab and varlilumab in relapsed or refractory B-cell malignancies: study protocol for a randomized controlled trial. Trials. 2018. PMID: 30413184. doi:10.1186/s13063-018-2996-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。